Cerevel Therapeutics
Clinical-stage biopharmaceutical company developing treatments for neuroscience disorders, including schizophrenia, epilepsy, and Parkinson's disease. Acquired by AbbVie in 2024 for $8.7 billion.
Website
https://www.cerevel.comLocation
Cambridge, Massachusetts, USA
Founded
2018
Categories
neuroscience, therapeutics, biotech, cns, psychiatry
Notes
Cerevel Therapeutics was a clinical-stage biopharmaceutical company focused on developing therapies for neuroscience disorders. The company was formed in 2018 through a collaboration between Bain Capital Life Sciences and Pfizer, leveraging Pfizer's neuroscience portfolio.
In August 2024, Cerevel was acquired by AbbVie for approximately $8.7 billion, representing one of the largest biopharma acquisitions of the year. The acquisition added Cerevel's promising pipeline of CNS therapies to AbbVie's portfolio.
Team (Pre-Acquisition)
- Ron Renaud - Former President & Chief Executive Officer
- LinkedIn: linkedin.com/in/ronrenaud
- Now CEO of Kailera Therapeutics
- Mark Altmeyer - Former Chief Commercial Officer
- John Renger, Ph.D. - Chief Scientific Officer
Additional Research Findings
- Acquired by AbbVie in August 2024 for $8.7 billion
- Former NASDAQ: CERE (now delisted following acquisition)
- Founded 2018 through Bain Capital Life Sciences and Pfizer partnership
- Pipeline included treatments for schizophrenia, epilepsy, Parkinson's disease
- Lead candidate: emraclidine (CVL-231) for schizophrenia
- Cambridge, Massachusetts headquarters
- Part of AbbVie's neuroscience portfolio post-acquisition